Jonathan Ledermann

University College London

United Kingdom

Research Interests

Explore related searches

Professors in United Kingdom

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

Articles (19)

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2021

Year:

2021

Collaborators (8)

isabelle ray coquard

professor

FRANCE

View details

Elspeth Payne

University College London

UNITED KINGDOM

View details

ANA OAKNIN

Head of Gynecological Cancer Program

Hospital Universitari Vall d'Hebron

SPAIN

View details

Mansoor Mirza

Chief Oncologist

Rigshospitalet

DENMARK

View details

Cristianne Rijcken

NETHERLANDS

View details

Sarah (Sally) J Lord

Associate Professor, Research

The University of Notre Dame Australia

AUSTRALIA

View details

Clare Scott

Walter and Eliza Hall Institute of Medical Research

AUSTRALIA

View details

Robert L. Coleman

UNITED STATES

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Jonathan Ledermann

Research Interests

Explore related searches

Contact this professor

Articles (19)

Rucaparib for maintenance treatment of platinum-sensitive, recurrent ovarian carcinoma: Final results of the phase 3, randomized, placebo-controlled ARIEL3 trial

Controversies in the organization and structure of management for rare tumors

Mechanisms of drug resistance: PARP inhibitors, antibody-drug-conjugates, and immunotherapy

Controversies and clinical unknowns in the use of PARP inhibitors in ovarian cancer

Poor Concordance Between Cancer Antigen-125 and RECIST Assessment for Progression in Patients With Platinum-Sensitive Relapsed Ovarian Cancer on Maintenance Therapy With a Poly(ADP-ribose) Polymerase Inhibitor

A multicenter retrospective study to assess feasibility, safety and efficacy of first-line carboplatin-paclitaxel versus carboplatin monotherapy in a frail, elderly epithelial ovarian cancer population

Monitoring clone dynamics and reversibility in clonal haematopoiesis and myelodysplastic neoplasm associated with PARP inhibitor therapy—a role for early monitoring and intervention

How long is long enough? An international survey exploring practice variations on the recommended duration of maintenance therapy with PARP inhibitors in patients with platinum sensitive recurrent ovarian cancer and long-term outcomes

Ethnicity and Socioeconomic Disparities in Clinical Trial Participation for Ovarian Cancer: A Retrospective Observational Study in London

An easy, fast, and accurate way for implementing the standards of care for the management of patients with endometrial carcinoma into daily clinical practice: the ESGO mobile app

CINOVA: a phase II study of CPC634 (nanoparticulate docetaxel) in patients with platinum resistant recurrent ovarian cancer

Evaluating open access publication and research impact in gynecologic oncology

Best original research presented at the 23rd European Congress on Gynaecological Oncology—Best of ESGO 2022

Ovarian Cancer Therapy: Homologous Recombination Deficiency as a Predictive Biomarker of Response to PARP Inhibitors

The path for medical associations to sponsor trustworthy guidelines: is it feasible?

Adjuvant and post-surgical treatment in high-grade epithelial ovarian cancer

British Gynaecological Cancer Society recommendations for women with gynecological cancer who received non-standard care during the COVID-19 pandemic

Prognostic nomogram for progression-free survival in patients with BRCA mutations and platinum-sensitive recurrent ovarian cancer on maintenance olaparib therapy following response to chemotherapy

Frontline Maintenance Treatment for Ovarian Cancer

Collaborators (8)

isabelle ray coquard

Elspeth Payne

ANA OAKNIN

Mansoor Mirza

Cristianne Rijcken

Sarah (Sally) J Lord

Clare Scott

Robert L. Coleman

Make your next move.